Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBAI NASDAQ:PTHL NASDAQ:QNRX NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBAICheck-Cap$1.44+3.6%$1.64$0.59▼$3.92$10.50M0.591.43 million shs73,498 shsPTHLPheton$0.34-16.0%$0.32$0.39▼$32.00$2.24M5.41.35 million shs187,158 shsQNRXQuoin Pharmaceuticals$4.65+10.7%$5.60$4.10▼$41.80$9.34M1.5668,409 shs41,971 shsVVOSVivos Therapeutics$0.58+0.9%$0.85$0.52▼$7.95$8.02M6.1859,606 shs396,110 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBAICheck-Cap0.00%+0.72%-21.47%-21.91%+138,999,900.00%PTHLPheton0.00%+21.43%+9.32%+6.45%-98.03%QNRXQuoin Pharmaceuticals0.00%-6.46%-27.46%-48.47%-49.88%VVOSVivos Therapeutics0.00%-33.83%-10.76%-56.00%-73.27%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBAICheck-Cap$1.44+3.6%$1.64$0.59▼$3.92$10.50M0.591.43 million shs73,498 shsPTHLPheton$0.34-16.0%$0.32$0.39▼$32.00$2.24M5.41.35 million shs187,158 shsQNRXQuoin Pharmaceuticals$4.65+10.7%$5.60$4.10▼$41.80$9.34M1.5668,409 shs41,971 shsVVOSVivos Therapeutics$0.58+0.9%$0.85$0.52▼$7.95$8.02M6.1859,606 shs396,110 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBAICheck-Cap0.00%+0.72%-21.47%-21.91%+138,999,900.00%PTHLPheton0.00%+21.43%+9.32%+6.45%-98.03%QNRXQuoin Pharmaceuticals0.00%-6.46%-27.46%-48.47%-49.88%VVOSVivos Therapeutics0.00%-33.83%-10.76%-56.00%-73.27%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBAICheck-Cap 1.00SellN/AN/APTHLPheton 1.00SellN/AN/AQNRXQuoin Pharmaceuticals 2.00HoldN/AN/AVVOSVivos Therapeutics 2.25Hold$2.80431.31% UpsideCurrent Analyst Ratings BreakdownLatest PTHL, MBAI, QNRX, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026QNRXQuoin Pharmaceuticals ThinkEquitySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy6/4/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $3.104/24/2026MBAICheck-Cap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/22/2026QNRXQuoin Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/22/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.004/20/2026VVOSVivos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026VVOSVivos Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $2.50(Data available from 6/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBAICheck-CapN/AN/A$0.57 per share2.45$0.47 per shareN/APTHLPheton$305.22K7.33N/AN/A$0.94 per share0.36QNRXQuoin PharmaceuticalsN/AN/AN/AN/A$15.64 per shareN/AVVOSVivos Therapeutics$17.44M0.42N/AN/A($0.16) per share-3.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBAICheck-Cap$4.14M-$2.77N/AN/AN/AN/AN/AN/AN/APTHLPheton-$660KN/AN/AN/AN/AN/AN/AN/AN/AQNRXQuoin Pharmaceuticals-$15.81M-$29.56N/AN/AN/AN/A-489.85%-221.29%8/6/2026 (Estimated)VVOSVivos Therapeutics-$21.17M-$2.14N/AN/AN/A-127.70%-2,325.64%-98.12%8/18/2026 (Estimated)Latest PTHL, MBAI, QNRX, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026VVOSVivos Therapeutics-$0.45-$0.52-$0.07-$0.52$4.35 million$5.14 million5/7/2026Q1 2026QNRXQuoin Pharmaceuticals-$2.17-$1.77+$0.40-$1.77N/AN/A4/15/2026Q4 2025VVOSVivos Therapeutics-$0.4950-$0.58-$0.0850-$0.58$7.10 million$3.82 million3/27/2026Q4 2025QNRXQuoin Pharmaceuticals-$6.42-$14.80-$8.38-$1.74N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthMBAICheck-CapN/AN/AN/AN/AN/APTHLPhetonN/AN/AN/AN/AN/AQNRXQuoin PharmaceuticalsN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBAICheck-CapN/A0.050.05PTHLPhetonN/AN/AN/AQNRXQuoin PharmaceuticalsN/A2.872.87VVOSVivos Therapeutics3.310.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBAICheck-Cap1.07%PTHLPhetonN/AQNRXQuoin Pharmaceuticals8.63%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipMBAICheck-Cap0.48%PTHLPhetonN/AQNRXQuoin Pharmaceuticals13.46%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBAICheck-Cap807.29 million7.25 millionN/APTHLPheton116.58 millionN/AN/AQNRXQuoin Pharmaceuticals42.01 million1.74 millionNot OptionableVVOSVivos Therapeutics16013.90 million13.60 millionOptionablePTHL, MBAI, QNRX, and VVOS HeadlinesRecent News About These CompaniesVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingJune 11, 2026 | globenewswire.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to ...June 10, 2026 | markets.businessinsider.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsJune 10, 2026 | globenewswire.comVivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | quiverquant.comQVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | globenewswire.comVivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial PositionJune 5, 2026 | quiverquant.comQVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingJune 5, 2026 | globenewswire.comVivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic ShiftsMay 29, 2026 | finance.yahoo.comVivos Therapeutics Balances Rapid Growth With Cash StrainMay 22, 2026 | tipranks.comVivos Therapeutics Earnings Call: Growth Meets Cash StrainMay 21, 2026 | tipranks.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 21, 2026 | finanznachrichten.deVivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call TranscriptMay 21, 2026 | seekingalpha.comVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 20, 2026 | globenewswire.comVivos Therapeutics Delays Quarterly FilingMay 15, 2026 | tipranks.comAnalysts see 200%+ upside in these 3 high-risk stocks: here's why?May 9, 2026 | invezz.comIVivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47April 29, 2026 | msn.comVivos Therapeutics Faces Nasdaq Listing Compliance ChallengesApril 22, 2026 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call TranscriptApril 17, 2026 | insidermonkey.comVivos Therapeutics Q4 Earnings Call HighlightsApril 17, 2026 | defenseworld.netDVivos Therapeutics Balances Growth Hopes With Cash StrainApril 16, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTHL, MBAI, QNRX, and VVOS Company DescriptionsCheck-Cap NASDAQ:MBAI$1.44 +0.05 (+3.60%) Closing price 04:00 PM EasternExtended Trading$1.44 +0.01 (+0.35%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.Pheton NASDAQ:PTHL$0.34 -0.06 (-16.03%) As of 06/12/2026Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.Quoin Pharmaceuticals NASDAQ:QNRX$4.65 +0.45 (+10.71%) Closing price 04:00 PM EasternExtended Trading$4.63 -0.02 (-0.43%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.Vivos Therapeutics NASDAQ:VVOS$0.58 +0.01 (+0.93%) Closing price 04:00 PM EasternExtended Trading$0.58 +0.00 (+0.47%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas What's Behind the Social Media Controversy Surrounding IonQ? Mission Control: Floating In SpaceX's Record-Breaking Orbit 3 Dividend Increases Investors Can Actually Trust RH’s Strong Q1 Still Leaves Investors With One Big Question SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? Alphabet's Most Overlooked Division Just Had a Big Week Robinhood Wants a Bigger Role in IPOs—Here's Why It Matters Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
